Concord Biotech IPO: Jhunjhunwala-backed Concord IPO sets price band at ₹705-741

-

 by Samiksha Chogule

Concord Biotech Ltd initial public offering (IPO) opens for subscription on Friday, August 4, and closes on Tuesday, August 8. The allocation to anchor investors for Concord Biotech IPO is scheduled to take place on Thursday, August 3. Concord Biotech IPO price band has been fixed in the range between ₹705 to ₹741 per equity share of face value of ₹1 each. Concord Biotech IPO lot size is 20 equity shares and in multiples of 20 equity shares thereafter.

Rekha Jhunjhunwala-backed Concord Biotech IPO consists of a pure offer-for-sale by Helix Investment Holdings Pte Ltd. of up to 20.93 million shares. The issue offer is priced at ₹1,550 crore on the upper band, and the firm is worth ₹7,752 crore.

20% of the company is owned by Helix Investment Holdings Pte Ltd, which is backed by Quadria Capital Fund LP, an Asian private equity fund with a focus on healthcare. Rakesh Jhunjhunwala owned 24.09% of the company through his asset management company RARE Enterprises (via RARE Trusts), which is now in the name of Rekha Jhunjhunwala. In 2004, Rekha and Rakesh Jhunjhunwala made an investment in Concord Biotech.

The book-running lead managers (BRLM) for the Concord Biotech IPO offer are Kotak Mahindra Capital Company Ltd, Citigroup Global Markets India Private Ltd, and Jefferies India Private Ltd, while Link Intime India Private Ltd is the registrar.

Concord Biotech IPO has reserved not more than 50% of the shares in the public issue for Qualified Institutional Buyers (QIB), not less than 15% for Non Institutional Investors (NII), and not less than 35% of the offer is reserved for Retail Investors.

Concord Biotech IPO date : Concord Biotech IPO's basis of allotment of shares will be finalised on Friday, August 11 and the company will initiate refunds on Monday, August 14, while the shares will be credited to the demat account of allottees on Thursday, 17 August. Concord Biotech IPO shares are likely to be listed on BSE and NSE on Friday, August 18.

Concord Biotech IPO GMP today : Concord Biotech IPO GMP or grey market premium is +325. This indicates Concord Biotech share price were trading at a premium of ₹325 in the grey market on Monday, according to topsharebrokers.com.

Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Concord Biotech share price is ₹1,066 apiece, which is 43.9% higher than the IPO price.

'Grey market premium' indicates investors' readiness to pay more than the issue price. In terms of market share, based on volume in 2022, Concord Biotech is an Ahmedabad-based biotechnology business that ranks among the top producers and developers of a select group of fermentation-based APIs used in immunosuppressants and cancer, according to F&S Report.

Concord Biotech exports goods to more than 70 nations, including regulated markets like the United States, Europe, Japan, and India. In 2022, it expects to hold a market share of more than 20% by volume for specific fermentation-based API products like mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. With presence in 20 states and five union territories in India, Concord Biotech has a total of 387 reactors and 41 industrial blocks, as per F&S Report.

Concord Biotech reported strong financial results for the fiscal year that ended in March FY23, with revenue and profit both up significantly from the prior year—each by 20% and 37.2%, respectively.

 

 

Comments

Post a Comment

Popular posts from this blog

Are ‘Unseen Forces’ Really Driving Political Vendetta Against Darwin Platform Chief Ajay Harinath Singh?

-
Image
by samikha   Mumbai, May, 2024: The scion of Lord Shri Ram's lineage, Darwin Platform Group of Companies (DGPC) Founder and Chairman Ajay Harinath Singh has found himself targeted by unseen forces with vested interests. Retaliating to these ‘unseen forces’ the Darwin Platform Chief emphasized that life threats and malicious campaigns, resulting from political vendetta make him more determined to fight the battle and expose them.  The whispers of a conspiracy began years ago, fueled by jealousy and fear of his growing influence in the 2000s. Coming from a Royal family of Sultanpur (Uttar Pradesh), his popularity in the state and Maharashtra unnerved many political parties that used to govern. Aligned with sacred lineage, his passion for nation-building and Hindutva made him popular among people and the BJP, however, this antagonized Congress and their current allies. Questions are many- Was the Congress party, in its bid to maintain its hold on power, orchestrating a campaign t...
Read more

Dell Technologies Reimagines Work with New PCs, Monitors and Software Experiences

-
Image
     by Samiksha   ·         Work smarter than ever before with the industry’s most intelligent [i] , secure [ii]  and sustainable [iii]  business PCs ·          5G-capable PCs and Microsoft Teams certified displays unlock enhanced connectivity and collaboration ·          Dell elevates sustainability standards with first commercial  PCs to use bioplastics from tree waste ·         Built-in low blue light and security technology enhance and secure the customer experience Bangalore, India -January, 2021;   Dell Technologies (NYSE:DELL) unveiled new products and software that reimagine work so anyone can perform at their best. With a new portfolio of intelligent, collaborative and sustainable devices, Dell is transforming work experiences to give people greater flexibility to work from anywhere. “Peopl...
Read more

‘Dennkur’ The World’s First Curcumin Pastille For Oral Health Care Launched

-
Image
The World’s First Curcumin Pastille For Oral Health Care Launched In Mumbai   Mumbai, March 07:  For the first time in the field of dentistry, Curcumin – a concentrated extract of turmeric with its excellent therapeutic effects has made its way as a pastille for preventive oral health care. This first of its kind pastille christened ‘Dennkur’ was launched in Mumbai yesterday and will be available with dentists across the country. The product has been introduced by Denteks, leading experts in dental technology of which Dr. Nirupam K Doctor and Dr. Lalit K Chokhani launched the breakthrough product in the presence of several eminent doctors and researchers. The 100 per cent ayurvedic and sugar-free medicine is backed by clinical and social trials and has proved to be highly effective in preventive and therapeutic applications in a variety of oral diseases including bleeding gums, receding gums, gingivitis, and periodontitis, among others. “...
Read more